SCHEMBL12311706

SCHEMBL12311706

CC(=O)NC(CCCCNC(=O)C(CS)NC(C)=O)C(N)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 1/20 0.57
SIRT1 Q96EB6 1/20 0.57
SIRT5 Q9NXA8 3/20 0.54
ALB P02768 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45
ALOX15 P16050 1/20 0.45
NFKB1 P19838 1/20 0.45
PTGS2 P35354 1/20 0.45
THPO P40225 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
PTPN2 P17706 2/20 0.41
PTPN1 P18031 2/20 0.41
CA1 P00915 4/20 0.40
CA2 P00918 4/20 0.40
TLR2 O60603 1/20 0.40
GRIA1 P42261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12311704 0.89 SIRT5 (0.52) SIRT6SIRT1SIRT5ALBSMN1; SMN2
SCHEMBL14601040 0.86 SIRT5 (0.65) SIRT6SIRT1SIRT5ALBSMN1; SMN2
SCHEMBL12892923 0.85 SIRT5 (0.55) SIRT6SIRT1SIRT5ALBSMN1; SMN2
SCHEMBL13635157 0.84 SIRT5 (0.65) SIRT6SIRT1SIRT5ALBSMN1; SMN2
SCHEMBL12311708 0.84 SIRT5 (0.65) SIRT6SIRT1SIRT5ALBSMN1; SMN2
SCHEMBL22020896 0.83 SIRT6 (0.54) SIRT6SIRT1SIRT5ALBSMN1; SMN2
SCHEMBL929209 0.83 KDM4E (0.52) SIRT6SIRT1SIRT5SMN1; SMN2KDM4E
SCHEMBL14682789 0.81 SIRT6 (0.62) SIRT6SIRT1SMN1; SMN2KDM4EMAPT
SCHEMBL930076 0.81 KDM4E (0.53) SIRT6SIRT1SIRT5SMN1; SMN2KDM4E
SCHEMBL13446714 0.80 SIRT5 (0.54) SIRT6SIRT1SIRT5ALBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133260-B2 GIP analog and hybrid polypeptides with selectable properties AMYLIN PHARMACEUTICALS, LLC (US) 2015-09-15 US disclosed
US-8895498-B2 GIP and exendin hybrid polypeptides ASTRAZENECA PHARMACEUTICALS, LP (US) 2014-11-25 US disclosed
US-20130281374-A1 DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES ASTRAZENECA PHARMACEUTICALS LP (US) 2013-10-24 US disclosed
US-20130196913-A1 GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES ASTRAZENECA PHARMACEUTICALS LP (US) 2013-08-01 US disclosed
US-8497240-B2 DPP-IV resistant GIP hybrid polypeptides with selectable properties AMYLIN PHARMACEUTICALS, LLC (US) 2013-07-30 US disclosed
US-20130137631-A1 GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES AMYLIN PHARMACEUTICALS, LLC (US) 2013-05-30 US disclosed
US-8404637-B2 GIP analog and hybrid polypeptides with selectable properties AMYLIN PHARMACEUTICALS, LLC (US) 2013-03-26 US disclosed
US-8263545-B2 GIP analog and hybrid polypeptides with selectable properties AMYLIN PHARMACEUTICALS, INC. (US) 2012-09-11 US disclosed
US-20110136737-A1 DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties AMYLIN PHARMACEUTICALS, INC. (US) 2011-06-09 US disclosed
US-20090036364-A1 GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES AMYLIN PHARMACEUTICALS, INC. (US) 2009-02-05 US disclosed
US-20080312157-A1 GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES AMYLIN PHARMACEUTICALS, INC. (US) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312157-A1 GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES GIPR, GLP1R, VIP SIRT6 4374/4885SIRT1 3123/4885SIRT5 4043/4885
US-20130196913-A1 GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES GIPR, GLP1R, VIP SIRT6 4374/4885SIRT1 3123/4885SIRT5 4043/4885
US-20110136737-A1 DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties GIPR, DPP4, GLP1R SIRT6 4268/4885SIRT1 3484/4885SIRT5 4286/4885
US-20090036364-A1 GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES GIPR, GLP1R, VIP SIRT6 4374/4885SIRT1 3123/4885SIRT5 4043/4885
US-20130281374-A1 DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES GIPR, DPP4, GLP1R SIRT6 4268/4885SIRT1 3484/4885SIRT5 4286/4885
US-20130137631-A1 GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES GIPR, GLP1R, VIP SIRT6 4374/4885SIRT1 3123/4885SIRT5 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.